RU2011109078A - Лечение легочной артериальной гипертензии - Google Patents
Лечение легочной артериальной гипертензии Download PDFInfo
- Publication number
- RU2011109078A RU2011109078A RU2011109078/04A RU2011109078A RU2011109078A RU 2011109078 A RU2011109078 A RU 2011109078A RU 2011109078/04 A RU2011109078/04 A RU 2011109078/04A RU 2011109078 A RU2011109078 A RU 2011109078A RU 2011109078 A RU2011109078 A RU 2011109078A
- Authority
- RU
- Russia
- Prior art keywords
- ness
- alkyl
- group
- mono
- zero
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title claims 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract 53
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 14
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 14
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 12
- -1 benzcycloalkyl Chemical group 0.000 claims abstract 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 11
- 239000001257 hydrogen Substances 0.000 claims abstract 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 11
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 11
- 125000003277 amino group Chemical group 0.000 claims abstract 10
- 125000004423 acyloxy group Chemical group 0.000 claims abstract 8
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 8
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 8
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 8
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 8
- 125000000714 pyrimidinyl group Chemical class 0.000 claims abstract 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims abstract 4
- 125000002947 alkylene group Chemical group 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- 125000005842 heteroatom Chemical group 0.000 claims abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 101100437773 Homo sapiens BMPR2 gene Proteins 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 229940127293 prostanoid Drugs 0.000 claims 1
- 150000003814 prostanoids Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8838208P | 2008-08-13 | 2008-08-13 | |
| US61/088,382 | 2008-08-13 | ||
| US16450109P | 2009-03-30 | 2009-03-30 | |
| US61/164,501 | 2009-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011109078A true RU2011109078A (ru) | 2012-09-20 |
Family
ID=41137217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011109078/04A RU2011109078A (ru) | 2008-08-13 | 2009-08-11 | Лечение легочной артериальной гипертензии |
Country Status (16)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2671029A1 (en) | 2009-06-30 | 2010-12-30 | James S. Baldassarre | Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension |
| AU2014205483B2 (en) | 2013-01-10 | 2017-11-30 | Gilead Sciences, Inc. | Non-selective kinase inhibitors |
| CA3172586C (en) * | 2013-07-31 | 2025-10-14 | Avalyn Pharma Inc. | IMATINIB AEROSOL COMPOUNDS AND RELATED USES |
| EP3054937B1 (en) | 2013-10-11 | 2023-07-26 | Pulmokine, Inc. | Spray dry formulations |
| WO2018081567A1 (en) | 2016-10-27 | 2018-05-03 | Pulmokine, Inc. | Combination therapy for treating pulmonary hypertension |
| BR112019009256A2 (pt) | 2016-11-08 | 2019-07-16 | Reata Pharmaceuticals Inc | métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo |
| WO2019157337A1 (en) * | 2018-02-08 | 2019-08-15 | Pulmokine, Inc. | Formulations of kinase inhibitors and prostanoids |
| US11464776B2 (en) | 2019-05-16 | 2022-10-11 | Aerovate Therapeutics, Inc. | Inhalable imatinib formulations, manufacture, and uses thereof |
| EP3968963A4 (en) | 2019-05-16 | 2023-02-01 | Aerovate Therapeutics, Inc. | IMATINIB FORMULATIONS, THEIR PREPARATION AND USES |
| WO2021108303A1 (en) * | 2019-11-25 | 2021-06-03 | PHPrecisionMed, LLC | Pharmaceutical compositions for the treatment of pulmonary hypertension |
| JP2023542298A (ja) * | 2020-09-11 | 2023-10-06 | プルモシム セラピューティクス リミテッド ライアビリティ カンパニー | 肺高血圧症を治療又は予防する組成物及び方法 |
| JP2023550407A (ja) | 2020-11-17 | 2023-12-01 | ユナイテッド セラピューティクス コーポレイション | 肺高血圧向けの吸入式イマチニブ |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AU2003272007A1 (en) * | 2002-10-25 | 2004-05-13 | The Administrators Of The Tulane Educational Fund | Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
| GB0325031D0 (en) * | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| CN101203224B (zh) * | 2005-01-28 | 2010-11-03 | 诺瓦提斯公司 | 嘧啶基氨基苯甲酰胺在制备治疗对Tie-2激酶活性的调节有响应的疾病的药物中的用途 |
| CA2606068C (en) * | 2005-05-02 | 2013-10-29 | Novartis Ag | Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome |
| ES2549327T3 (es) * | 2005-12-06 | 2015-10-27 | Novartis Ag | Derivados de pirimidilaminobenzamida para el tratamiento de la neurofibromatosis |
| JP2010509349A (ja) * | 2006-11-03 | 2010-03-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
-
2009
- 2009-08-11 WO PCT/US2009/053358 patent/WO2010019540A1/en not_active Ceased
- 2009-08-11 CA CA2732789A patent/CA2732789A1/en not_active Abandoned
- 2009-08-11 KR KR1020117005744A patent/KR20110053354A/ko not_active Withdrawn
- 2009-08-11 RU RU2011109078/04A patent/RU2011109078A/ru not_active Application Discontinuation
- 2009-08-11 US US13/058,742 patent/US20110190313A1/en not_active Abandoned
- 2009-08-11 CN CN2009801314677A patent/CN102123711A/zh active Pending
- 2009-08-11 BR BRPI0917491A patent/BRPI0917491A2/pt not_active IP Right Cessation
- 2009-08-11 JP JP2011523078A patent/JP2011530607A/ja active Pending
- 2009-08-11 AU AU2009282104A patent/AU2009282104A1/en not_active Abandoned
- 2009-08-11 MX MX2011001668A patent/MX2011001668A/es not_active Application Discontinuation
- 2009-08-11 NZ NZ590839A patent/NZ590839A/xx not_active IP Right Cessation
- 2009-08-11 EP EP09791358A patent/EP2315592A1/en not_active Withdrawn
- 2009-08-12 TW TW098127172A patent/TW201010999A/zh unknown
-
2011
- 2011-01-27 IL IL210922A patent/IL210922A0/en unknown
- 2011-02-11 CL CL2011000295A patent/CL2011000295A1/es unknown
- 2011-03-07 MA MA33678A patent/MA32617B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201010999A (en) | 2010-03-16 |
| WO2010019540A1 (en) | 2010-02-18 |
| CL2011000295A1 (es) | 2011-07-15 |
| CN102123711A (zh) | 2011-07-13 |
| MX2011001668A (es) | 2011-03-25 |
| EP2315592A1 (en) | 2011-05-04 |
| JP2011530607A (ja) | 2011-12-22 |
| CA2732789A1 (en) | 2010-02-18 |
| IL210922A0 (en) | 2011-04-28 |
| US20110190313A1 (en) | 2011-08-04 |
| BRPI0917491A2 (pt) | 2015-12-01 |
| KR20110053354A (ko) | 2011-05-20 |
| MA32617B1 (fr) | 2011-09-01 |
| AU2009282104A1 (en) | 2010-02-18 |
| NZ590839A (en) | 2013-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011109078A (ru) | Лечение легочной артериальной гипертензии | |
| JP2011530607A5 (cg-RX-API-DMAC7.html) | ||
| EP3028702B1 (en) | Methods of treatment using selective bcl-2 inhibitors | |
| PE20241707A1 (es) | Composicion farmaceutica que comprende un compuesto de quinazolina | |
| RU2011137399A (ru) | Гетероциклическое производное | |
| RU2012124811A (ru) | СПОСОБ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ДРУГИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ АКТИВНОСТЬЮ КИНАЗ Bcr-Abl, c-Kit, DDR1, DDR2, ИЛИ PDGF-R | |
| JP2018502877A5 (cg-RX-API-DMAC7.html) | ||
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| JOP20200042A1 (ar) | مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها | |
| RU2012147511A (ru) | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза | |
| CA3094449A1 (en) | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| AR077468A1 (es) | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa | |
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| RU2014136339A (ru) | Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов | |
| RU2012120901A (ru) | Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r | |
| AR070220A1 (es) | Amino-bencimidazoles sustituidos medicamentos que comprenden dicho compuestos, uso y metodos de fabricacion de los mismos | |
| WO2020092618A9 (en) | Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin | |
| RU2304436C2 (ru) | Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболеваний, подобных аллергическим нарушениям | |
| RU2014144951A (ru) | Новое 1-замещенное производное индазола | |
| RU2011105059A (ru) | Применение производных пиримидиламинобензамида для лечения фиброза | |
| AU2002307140A1 (en) | Use of N-Phenyl-2-Pyrimidineamine Derivatives against mast cell-based diseases like allergic disorders | |
| MY146403A (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
| RU2008114048A (ru) | Комбинации, включающие ингибитор рецептора сэфр (сосудистого эндотелиального фактора роста) и агент, увеличивающий проницаемость | |
| RU2015110256A (ru) | Бензофуразановые антимилоидные соединения и способы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20131007 |